Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Burden of Nonrheumatic Valvular Heart Diseases in Iran Between 1990 and 2017: Results From the Global Burden of Disease Study 2017 Publisher



Arabloo J1 ; Omidi N2 ; Rezapour A1 ; Sarabi Asiabar A1 ; Mojtaba Ghorashi S2 ; Azari S3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Health Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran
  2. 2. Cardiovascular Disease Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Hospital Management Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran

Source: IJC Heart and Vasculature Published:2022


Abstract

Background: Nonrheumatic valvular heart diseases (NRVDs) are some of the common and treatable cardiovascular diseases. The objective of this study was to describe the burden of NRVDs in Iran from 1990 to 2017 and to compare the findings with those from the world and in particular, the North Africa and Middle East (NAME) region. Methods: Using publicly available estimates from the Global Burden of Disease 2017 Study (the GBD 2017 Study) for Iran and the NAME region, we reported the years of life lost (YLLs), years lived with disability (YLDs), disability-adjusted life years (DALYs), and the prevalence for NRVDs by age group and sex between 1990 and 2017. Results: There were an estimated 174,071 cases and 957 deaths from NRVDs in Iran in 2017. In addition, 1844 YLDs, 21,661 YLLs, and 23,506 DALYs were caused by NRVDs in Iran in 2017. Between 1990 and 2017, the age-standardized prevalence rate increased in Ian by 15%, the death rate by 15.3%, and DALYs by 2%. Nevertheless, in the world and the NAME region, the age-standardized rates for DALYs and deaths decreased and the age-standardized prevalence rate increased till 2017. Conclusions: The burden of NRVDs is on the rise in Iran. A reduction in the burden of NRVDs in Iran requires the development of appropriate plans to meet the health needs of patients, the decrease of the modifiable risk factors, the allocation of adequate resources for the early diagnosis and management of the diseases, and an improvement in access to treatment technologies. © 2022
Related Docs
1. Effectiveness of an Individualized Internet-Based Physical Activity Program: A Randomized Controlled Trial, European Journal of Integrative Medicine (2021)
2. A Systematic Review of the Cost-Effectiveness of Heart Valve Replacement With a Mechanical Versus Biological Prosthesis in Patients With Heart Valvular Disease, Heart Failure Reviews (2020)
3. Burden of Hypertensive Heart Disease in Iran During 1990-2017: Findings From the Global Burden of Disease Study 2017, PLoS ONE (2021)
4. Interplay Between Fatty Acid Desaturase2 (Fads2) Rs174583 Genetic Variant and Dietary Antioxidant Capacity: Cardio-Metabolic Risk Factors in Obese Individuals, BMC Endocrine Disorders (2022)
Experts (# of related papers)
View all Related Experts
Negar Omidi (2)
Mojtaba Salarifar (1)